Sequence: ehGehGehGehG-hydrazone-RRRRRRRR
| Experiment Id | EXP000366 |
|---|---|
| Paper | Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide- |
| Peptide | ACPP-R8 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | very high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 3 mol% of total lipids (DSPE-PEG2000-ACPP) |
| Rna Concentration | 100–200 nM (in vitro) |
| Mixing Ratio | Encapsulated in liposomes (thin-film hydration) |
| Formulation Format | ACPP-modified liposome |
| Formulation Components | SPC/Chol/DC-Chol/DSPE-mPEG2000 liposome + DSPE-PEG2000-ACPP + siRNA |
| Size Nm | 200.00 |
| Zeta Mv | 40.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MCF-7 breast cancer cells; A549 lung cancer cells |
| Animal Model | |
| Administration Route | |
| Output Type | Gene silencing; apoptosis; uptake; endosomal escape |
| Output Value | Significant PLK-1 knockdown and apoptosis at pH 6.2; minimal activity at pH 7.4 |
| Output Units | |
| Output Notes | pH-responsive activation of ACPP restores CPP activity in acidic tumor-like conditions; strong cytosolic siRNA distribution and lysosomal avoidance shown by confocal microscopy |
| Toxicity Notes | No significant toxicity reported at effective doses |
| Curation Notes |